These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26616466)

  • 1. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS-102 for the treatment of metastatic colorectal cancer.
    Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
    Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review on TAS-102 development and its use for metastatic colorectal cancer.
    Mota JM; Fonseca LG; Braghiroli MI; Hoff PM
    Crit Rev Oncol Hematol; 2016 Aug; 104():91-7. PubMed ID: 27296058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
    van der Velden DL; Opdam FL; Voest EE
    Clin Cancer Res; 2016 Jun; 22(12):2835-9. PubMed ID: 27126991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review.
    Zaniboni A; Bertocchi P; Barni S; Petrelli F
    Clin Colorectal Cancer; 2016 Dec; 15(4):292-297. PubMed ID: 27431756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAS-102, a novel antitumor agent: a review of the mechanism of action.
    Lenz HJ; Stintzing S; Loupakis F
    Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Agent Therapies After Standard Combination Regimens.
    Chokshi S; Hochster HS
    Cancer J; 2016; 22(3):205-10. PubMed ID: 27341600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS-102 in metastatic colorectal cancer.
    Burki TK
    Lancet Oncol; 2018 Jan; 19(1):e18. PubMed ID: 29249306
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)].
    Kitao H; Matsuoka K; Iimori M; Tokunaga E; Saeki H; Oki E; Miyamoto Y; Baba H; Maehara Y
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):8-14. PubMed ID: 26809521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
    Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
    Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.